Addendum

Alectinib (non-small-cell lung cancer) - Addendum to commission A17-19

Report documents

Indication:

Advanced ALK-positive NSCLC (lung cancer)

Result of dossier assessment:

Hint of considerable added benefit for crizotinib and chemotherapy-pretreated adults who are eligible for treatment with docetaxel or pemetrexed

2017-10-19 A G-BA decision was published.

Project no.: A17-44
Commission: Commission awarded on 04.09.2017 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.